CAS 78281-72-8|Nepafenac
| Common Name | Nepafenac | ||
|---|---|---|---|
| CAS Number | 78281-72-8 | Molecular Weight | 254.284 |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 562.5±50.0 °C at 760 mmHg |
| Molecular Formula | C15H14N2O2 | Melting Point | 177-181ºC |
| MSDS | USA | Flash Point | 294.0±30.1 °C |
| Symbol | GHS09 | Signal Word | Warning |
Names
| Name | nepafenac |
|---|---|
| Synonym | More Synonyms |
Nepafenac BiologicalActivity
| Description | Nepafenac(AHR 9434; AL 6515; Nevanac) is a selective COX-2 inhibitor; is prodrug of Amfenac.IC50 value:Target: COX-2Nepafenac is a NSAID (nonsteroidal anti inflammatory drug) that is routinely used in opthamology to control pain following cataract surgery. |
|---|---|
| Related Catalog | Research Areas >>Inflammation/Immunology |
| Target | COX-1:64.3 μM (IC50) COX-2 |
| References | [1]. Gamache DA, Graff G, Brady MT et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70. [2]. Ke TL, Graff G, Spellman JM, Yanni JM. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84. [3]. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006 Feb;22(2):397-404. [4]. Marshall JC, Fernandes BF, Di Cesare S et al. The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma. Carcinogenesis. 2007 Sep;28(9):2053-8. [5]. Singh R, Alpern L, Jaffe GJ et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6:1259-69. |
Chemical & Physical Properties
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 562.5±50.0 °C at 760 mmHg |
| Melting Point | 177-181ºC |
| Molecular Formula | C15H14N2O2 |
| Molecular Weight | 254.284 |
| Flash Point | 294.0±30.1 °C |
| Exact Mass | 254.105530 |
| PSA | 86.18000 |
| LogP | 0.73 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.641 |
| InChIKey | QEFAQIPZVLVERP-UHFFFAOYSA-N |
| SMILES | NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N |
| Storage condition | Refrigerator |
Safety Information
| Symbol | GHS09 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H400 |
| Precautionary Statements | P273 |
| Hazard Codes | N |
| Risk Phrases | 50/53 |
| Safety Phrases | 60-61 |
| RIDADR | UN 3077 9 / PGIII |
| HS Code | 2924299090 |
Customs
| HS Code | 2924299090 |
|---|---|
| Summary | 2924299090. other cyclic amides (including cyclic carbamates) and their derivatives; salts thereof. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0% |
Articles1
More Articles| Use of nepafenac (Nevanac) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin. Ophthalmol. 4 , 1249-52, (2010) The purpose of this study is to determine the efficacy of combining topical nepafenac with monthly intravitreal injections of ranibizumab or bevacizumab in the treatment of recalcitrant exudative macu... |
Synonyms
| Benzeneacetamide, 2-amino-3-benzoyl- |
| Nevanac |
| 2-(2-Amino-3-benzoylphenyl)acetamide |
| Nepafenac |
| Nepafanac |
| 2-Amino-3-benzoylbenzeneacetamide |
| 2-[2-amino-3-(phénylcarbonyl)phényl]acétamide |
| AL 6515 |
| AHR 9434 |
| 2-[2-Amino-3-(phenylcarbonyl)phenyl]acetamid |
| 2-[2-amino-3-(phenylcarbonyl)phenyl]acetamide |
| 2-Amino-3-benzoyl-phenylacetamide |
